Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Colorectal Neoplasms 1422Pancreatic Neoplasms 847Carcinoma, Hepatocellular 736Stomach Neoplasms 639Colonic Neoplasms 441Rectal Neoplasms 400Esophageal Neoplasms 395Carcinoma, Non-Small-Cell Lung 328Breast Neoplasms 328Neoplasms 300Liver Neoplasms 280Cholangiocarcinoma 242Ovarian Neoplasms 240Lung Neoplasms 238Neoplasm Metastasis 237Gastrointestinal Neoplasms 216Melanoma 184Prostatic Neoplasms 162Esophageal Squamous Cell Carcinoma 160Biliary Tract Neoplasms 160Endometrial Neoplasms 141Squamous Cell Carcinoma of Head and Neck 128Uterine Cervical Neoplasms 127Carcinoma, Renal Cell 113Head and Neck Neoplasms 112Sarcoma 100Urinary Bladder Neoplasms 95Adenocarcinoma Of Esophagus 89Triple Negative Breast Neoplasms 84Anus Neoplasms 83

Interventions

olaparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian × Gastrointestinal × 1 year × Clear all
NCT01078662 2025-08-13

Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats

AstraZeneca

Phase 2 Completed
298 enrolled 18 charts
BreastGastrointestinalGenitourinaryGynecologic

Ovarian

Data powered by HemOnc (CC BY 4.0) Colophon âš¡